Anika Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
20,574.50
38,319.50
30,758.00
32,547.00
31,816.00
18,722
Depreciation, Depletion & Amortization
4,772.50
4,705.60
3,775.00
3,734.00
4,290.00
5,910
Other Funds
856.80
3,277.20
847.00
647.00
-
15,303
Funds from Operations
27,769.20
36,199.40
36,109.00
39,667.00
43,169.00
38,118
Changes in Working Capital
2,604.20
3,779.00
2,955.00
15,866.00
2,357.00
3,200
Net Operating Cash Flow
25,165.00
39,978.40
39,064.00
23,801.00
40,812.00
34,918
Capital Expenditures
440.90
1,552.90
9,225.00
14,014.00
8,980.00
Sale of Fixed Assets & Businesses
187.70
-
-
-
-
Purchase/Sale of Investments
-
6,750.00
21,001.00
7,251.00
3,500.00
Net Investing Cash Flow
253.20
8,302.90
30,226.00
6,763.00
12,480.00
Issuance/Reduction of Debt, Net
9,600.00
-
-
-
-
Net Financing Cash Flow
5,689.20
5,331.90
1,921.00
23,346.00
314.00
Net Change in Cash
19,265.70
36,822.70
10,551.00
6,446.00
28,995.00
Free Cash Flow
24,724.10
38,425.50
29,839.00
9,787.00
31,832.00
Deferred Taxes & Investment Tax Credit
2,205.60
815.20
747.00
65.00
1,198.00
1,817
Change in Capital Stock
3,053.90
2,054.70
1,074.00
23,993.00
314.00
Exchange Rate Effect
43.10
184.60
208.00
138.00
349.00

About Anika Therapeutics

View Profile
Address
32 Wiggins Avenue
Bedford Massachusetts 01730
United States
Employees -
Website http://www.anikatherapeutics.com
Updated 07/08/2019
Anika Therapeutics, Inc. is global medical technology company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical and veterinary.